The identification of location of the production site of a new pharmaceutical company, NovaMedica, a joint enterprise between the Russian high-technology investment fund RusNano and the American venture health care fund Domain Associates (The Pharma Letter March 7), will be chosen at the end of the first quarter of 2013.
NovaMedica was established in the frameworks of the cooperation agreement, which was signed by RusNano and Domain Associates in March 2012. The partnership involves joint investment in advanced medical technologies and innovative drugs, and bringing these to market in Russia and the Community of Independent States (CIS) for their development, manufacture, and commercialization, including the creation of a GMP production facility.
In their earlier announcement, the partners each pledged to invest $380 million and to build a $190 million production facility in Russia planned to launch it in 2015. The plant will produce over 200 million pills or 20 million packages per year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze